The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

Now Viewing

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

Video content above is prompted by the following questions:

• Please describe the economic burden of RSV, especially in adults aged 50-59 and those 60 and older.
• What are the main drivers of healthcare resource utilization in high-risk patients with RSV?
  

Related Videos

Related Content

Advertisement

July 2nd 2024

Which Demographic, Environmental Factors Have Higher Risks for RSV Hospitalization?

Pearl Steinzor

Knowledge on respiratory syncytial virus (RSV) risk factors may help inform public health authorities on high-risk populations, researchers suggest.

June 26th 2024

Why Are Some Parents Still Hesitant to Vaccinate Their Child Against RSV?

Pearl Steinzor

Increasing knowledge of the vaccine-preventable disease will ultimately improve vaccine uptake among target groups, researchers suggest.

June 18th 2024

Simultaneous RSV, Influenza Vaccination Found Safe in Patients With High-Risk Heart Failure

Pearl Steinzor

Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).

June 11th 2024

FDA Approves Expanded Age Indication for RSV Vaccine Arexvy

Pearl Steinzor

The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.

June 7th 2024

How COVID-19 Has Impacted RSV Epidemiology Among Children in a Hospital Setting

Pearl Steinzor

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.

May 31st 2024

Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine

Cameron Santoro

The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.

Related Content

Advertisement

July 2nd 2024

Which Demographic, Environmental Factors Have Higher Risks for RSV Hospitalization?

Pearl Steinzor

Knowledge on respiratory syncytial virus (RSV) risk factors may help inform public health authorities on high-risk populations, researchers suggest.

June 26th 2024

Why Are Some Parents Still Hesitant to Vaccinate Their Child Against RSV?

Pearl Steinzor

Increasing knowledge of the vaccine-preventable disease will ultimately improve vaccine uptake among target groups, researchers suggest.

June 18th 2024

Simultaneous RSV, Influenza Vaccination Found Safe in Patients With High-Risk Heart Failure

Pearl Steinzor

Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).

June 11th 2024

FDA Approves Expanded Age Indication for RSV Vaccine Arexvy

Pearl Steinzor

The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.

June 7th 2024

How COVID-19 Has Impacted RSV Epidemiology Among Children in a Hospital Setting

Pearl Steinzor

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.

May 31st 2024

Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine

Cameron Santoro

The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.